PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Metsä Board Oyj (METSA.HE)
5.580.04 (-0.71%)
5.38 - 5.60
4.95 - 8.28
2.3K / 2.4K (Avg.)
-279.00 | -0.02
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-14.94%
Both firms have declining sales. Martin Whitman would suspect an industry slump or new disruptive entrants.
-51.13%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
-1553.85%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-1553.85%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-533.33%
Negative net income growth while STERV.HE stands at 296.22%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-472.73%
Negative EPS growth while STERV.HE is at 300.00%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-472.73%
Negative diluted EPS growth while STERV.HE is at 300.00%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
10.58%
Slight or no buybacks while STERV.HE is reducing shares. John Neff might see a missed opportunity if the company’s stock is cheap.
10.58%
Slight or no buyback while STERV.HE is reducing diluted shares. John Neff might consider the competitor’s approach more shareholder-friendly.
No Data
No Data available this quarter, please select a different quarter.
-27.78%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-1800.00%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
-17.46%
Both companies have negative long-term revenue/share growth. Martin Whitman would question if the entire market or product set is shrinking.
-17.46%
Both face negative 5Y revenue/share CAGR. Martin Whitman would suspect macro headwinds or obsolete product offerings across the niche.
-17.46%
Negative 3Y CAGR while STERV.HE stands at 4.16%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
-69.73%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-69.73%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
-69.73%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
-193.38%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-193.38%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
-193.38%
Negative 3Y CAGR while STERV.HE is 114.98%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
-23.72%
Both are negative. Martin Whitman suspects the segment is in decline or saddled with persistent unprofitability or write-downs.
-23.72%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-23.72%
Negative 3Y equity/share growth while STERV.HE is at 3.33%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-13.21%
Both reduce inventory yoy. Martin Whitman suspects a broader move to lean operations or industry slowdown in demand.
-5.45%
Negative asset growth while STERV.HE invests at 0.39%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-28.18%
We have a declining book value while STERV.HE shows 0.98%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-4.21%
We’re deleveraging while STERV.HE stands at 0.64%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.